These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 31019975

  • 1. Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
    Wang W, Hu Z, Huang Y, Zheng H, Sun Q, Yang Q, Zhang Y, Zhang L, Wang W.
    Biomed Res Int; 2019; 2019():9205851. PubMed ID: 31019975
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic implication of HER2 in advanced biliary tract cancer.
    Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
    Oncotarget; 2016 Sep 06; 7(36):58007-58021. PubMed ID: 27517322
    [Abstract] [Full Text] [Related]

  • 3. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
    Yu Y, Wang J, Xia N, Li B, Jiang X.
    Oncol Rep; 2015 Apr 06; 33(4):1683-90. PubMed ID: 25633045
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α.
    Gao H, Xie J, Peng J, Han Y, Jiang Q, Han M, Wang C.
    Exp Cell Res; 2015 Mar 15; 332(2):236-46. PubMed ID: 25499970
    [Abstract] [Full Text] [Related]

  • 8. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
    Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F.
    BMC Cancer; 2010 Nov 18; 10():631. PubMed ID: 21087480
    [Abstract] [Full Text] [Related]

  • 9. Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB.
    Zhang DC, Liu JL, Ding YB, Xia JG, Chen GY.
    Acta Pharmacol Sin; 2013 Feb 18; 34(2):301-8. PubMed ID: 23274410
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
    Iwase R, Haruki K, Fujiwara Y, Furukawa K, Shiba H, Uwagawa T, Misawa T, Ohashi T, Yanaga K.
    J Surg Res; 2013 Sep 18; 184(1):605-12. PubMed ID: 23830367
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
    Tanizaki J, Okamoto I, Takezawa K, Tsukioka S, Uchida J, Kiniwa M, Fukuoka M, Nakagawa K.
    Mol Cancer Ther; 2010 May 18; 9(5):1198-207. PubMed ID: 20424000
    [Abstract] [Full Text] [Related]

  • 15. Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient.
    Wang L, Li X, Cheng Y, Yang J, Liu S, Ma T, Luo L, Hu Y, Cai Y, Yan D.
    Front Immunol; 2021 May 18; 12():784861. PubMed ID: 35069555
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.
    Zhan M, Yang RM, Wang H, He M, Chen W, Xu SW, Yang LH, Liu Q, Long MM, Wang J.
    Cancer Commun (Lond); 2018 Jul 17; 38(1):48. PubMed ID: 30016995
    [Abstract] [Full Text] [Related]

  • 19. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.
    Cancer Res; 2009 Dec 15; 69(24):9330-6. PubMed ID: 19934333
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.